{"database":"MetabolomicsWorkbench","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["http://www.metabolomicsworkbench.org/rest/study/study_id/ST001186/mwtab"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Metabolomics"],"technology_type":["Mass Spectrometry","ESI"],"disease":["Huntingtons Disease"],"species":["Mus Musculus"],"full_dataset_link":["http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001186"],"study_factor":["Time:3 | Treatment:Dimethyl fumarate","Time:1 | Treatment:4-Deoxypyridoxine","Time:1 | Treatment:Sodium Butyrate","Time:2 | Treatment:Trichostatin A","Time:3 | Treatment:Cyproheptadine","Time:3 | Treatment:Loxapine","Time:2 | Treatment:Q111SST_Control","Time:1 | Treatment:Selisistat","Time:3 | Treatment:Trichostatin A","Time:2 | Treatment:Cyproheptadine","Time:1 | Treatment:Clioquinol","Time:1 | Treatment:Q7SST_Control","Time:1 | Treatment:Haloperidol","Time:3 | Treatment:Cysteamine","Time:2 | Treatment:4-Deoxypyridoxine","Time:1 | Treatment:Cyproheptadine","Time:2 | Treatment:Fingolimod phosphate","Time:2 | Treatment:Pizotifen","Time:2 | Treatment:Loxapine","Time:1 | Treatment:Trichostatin A","Time:3 | Treatment:Diacylglycerol kinase inhibitor II","Time:2 | Treatment:Sodium Butyrate","Time:1 | Treatment:Pizotifen","Time:3 | Treatment:Haloperidol","Time:3 | Treatment:Clioquinol","Time:2 | Treatment:Cysteamine","Time:2 | Treatment:Diacylglycerol kinase inhibitor II","Time:3 | Treatment:Meclizine","Time:1 | Treatment:Dimethyl fumarate","Time:1 | Treatment:Meclizine","Time:1 | Treatment:Loxapine","Time:3 | Treatment:Selisistat","Time:3 | Treatment:Pizotifen","Time:1 | Treatment:Nortriptyline","Time:2 | Treatment:Meclizine","Time:1 | Treatment:Q111SST_Control","Time:3 | Treatment:4-Deoxypyridoxine","Time:2 | Treatment:Nicotinamide","Time:3 | Treatment:Sodium Butyrate","Time:1 | Treatment:Cysteamine","Time:2 | Treatment:Nortriptyline","Time:2 | Treatment:Q7SST_Control","Time:3 | Treatment:Fingolimod phosphate","Time:3 | Treatment:Nicotinamide","Time:1 | Treatment:Diacylglycerol kinase inhibitor II","Time:1 | Treatment:Fingolimod phosphate","Time:2 | Treatment:Dimethyl fumarate","Time:2 | Treatment:Selisistat","Time:3 | Treatment:Nortriptyline","Time:2 | Treatment:Clioquinol","Time:3 | Treatment:Q111SST_Control","Time:1 | Treatment:Nicotinamide","Time:3 | Treatment:Q7SST_Control","Time:2 | Treatment:Haloperidol"],"tissue":["Cultured Cells"],"submitter_affiliation":["Massachusetts Institute of Technology"],"sample_protocol":["Normal phase POSITIVE ION MODE. Normal phase NEGATIVE ION MODE. HILIC POSITIVE ION MODE. HILIC NEGATIVE ION MODE."],"repository":["MetabolomicsWorkbench"],"data_protocol":[""],"name_synonyms":["preventive measures, Controlling, preventive therapy, reference sample, control, prophylaxis, Metabonomic, Cell., Metabonomics, Metabolomic, prevention and control, Cell, Controlled, prevention"],"sample_synonyms":["average, average."],"additional_accession":[]},"is_claimable":false,"name":"Untargeted metabolomics on control and compound-treated STHdhQ111 cells and control STHdhQ7 cells","description":null,"dates":{"publication":""},"accession":"ST001186","cross_references":{"TAXONOMY":["10090"]}}